Posted inOpinion

OP-ED | HB 6447 Means Well, But Will Stifle Pharmaceutical Innovation In Connecticut

The world has waited anxiously for vaccines and treatments to bring an end to the COVID-19 pandemic. Pharmaceutical companies banded together in ways we didn’t realize were possible, to form research, manufacturing, and distribution partnerships, collaborating to ensure the vaccines and treatments being developed could get to the people who need them as fast as possible.